The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
BURLINGTON, Mass., May 11, 2026 /PRNewswire/ -- SQ Innovation today announced topline results from the SUBCUT HF II trial of its product Lasix® ONYU, a novel subcutaneous formulation of furosemide for ...
Results of SUBCUT HF II, the first full-scale outcomes trial of subcutaneous furosemide for at-home treatment of edema in heart failure patients, to be released on May 9th at international heart ...
FDA approved a subcutaneous furosemide autoinjector with IV-equivalent exposure for edema in adults with HF or CKD, expanding the Furoscix franchise beyond the on-body infusor. Rapid administration ...
BURLINGTON, Mass., Oct. 8, 2025 /PRNewswire/ -- SQ Innovation, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination Lasix® ONYU (furosemide ...
BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results